One such study involves pancreatic cancer patients undergoing a “prime-boost” regimen, starting with a vaccine using recombinant Listeria bacteria expressing the tumor antigen mesothelin, followed by a G-Vax vaccine derived from two allogeneic pancreatic cancer cell lines [126, 127]. Here, MSLN is linked to pancreatic neoplasm.